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COMMENTARY: HEALTH CARE COST
CONTAINMENT AND TECHNOLOGY
ASSESSMENT
Seymour Perry * & Flora Chu**
INTRODUCTION
NEW FORCES IN the delivery and financing of health care,
namely the pressures of cost containment and market competi-
tion, have led to an increasing demand for rational, formalized
mechanisms to assess new and existing technologies. Professor
Mehlman has set out to address comprehensively the question of
how to determine which technologies are wasteful, and how to
translate these findings into cost savings. He explores the scope of
technology-assessment activity, the observed and potential impacts
of such activity on the acquisition of technology, and its use by reg-
ulatory bodies in an effort to control costs. He identifies and de-
scribes the important parties responsible for technology-assessment
activities and delineates the inherent problems in performing assess-
ments, emphasizing two dilemmas: the problem of perspective and
of determining the value of intangible benefits. He details the legal
precedents and implications of a cost-conscious approach to the dif-
fusion of technologies, particularly in the unique fiduciary relation-
ship between the provider and the patient.
In a field spanning various disciplines and encompassing the in-
terests and well-being of many different parties, Professor Mehlman
has very capably grasped the essential issues which continue to
complicate technology-assessment efforts. The author outlines the
many incentives and disincentives in the current medical-legal cli-
mate to adopt costly, beneficial technologies, and concludes that it
is yet uncertain which pressures will prevail. He demonstrates a
comprehensive grasp of the structure and workings of the Prospec-
tive Payment System (PPS), instituted three years ago in an effort to
control costs in the Medicare hospital program.
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In his conclusion, Professor Mehlman proposes an approach to
technology assessment which emphasizes patients' interests and fo-
cuses on the safety, effectiveness, and cost-effectiveness of technolo-
gies. In this Commentary, we would like to address a few of the
issues identified by Professor Mehlman in his discussion, providing
some elaboration and perhaps complementing his views with our
own perspectives.
I. THE CONTEXT: THE ROLE OF PUBLIC PERCEPTION
AND TECHNOLOGY
A. Public Opinion On Health Care Cost Containment
There is virtual universal agreement that health care costs must
be brought under control, and this conviction has constituted the
basis for the cascade of recent cost-containment initiatives. Never-
theless, it is interesting to note that public opinion has not clearly
evidenced a rise in concern to a level justifying revolutionary re-
forms. Although public opinion surveys have repeatedly indicated
that the public regards rising costs as the most important problem
in health care today, they also reveal that the public does not wish
to significantly change their own arrangements for care.1 Even with
the spectre of the federal deficit looming large, two out of three
Americans think that federal health care expenditures should be in-
creased. Only twenty-one percent wish to limit the use of new,
costly technologies, but seventy-four percent do support the region-
alization of very expensive equipment.
Health care cost-control measures should take into account the
public's opinion, high expectations, and valuation of health care
services in order to maintain public trust and confidence.2 Thus, as
Professor Mehlman has highlighted in his article, the assessment of
technologies, within the system of checks and balances, should be
based in large part on patient-centered values, and the patient
should have reasonable opportunities for appeal and review if a
technology is denied or not covered. In particular, Professor Mehl-
man has suggested that the public is entitled to three things: clarifi-
cation of the extent of Medicare coverage for technology, adequate
public recourse to appeal, and assurance that quality standards will
be enforced.
1. See Blendon & Altman, Special Report: Public Attitudes About Health-Care Costs
A Lesson in National Schizophrenia, 311 NEw ENG. J. MED. 613 (1984).
2. Id. at 614.
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B. Factors Contributing to the Technological Imperative
Professor Mehlman describes the "technological imperative" as
a phenomenon leading to the inappropriate and excessive develop-
ment, acquisition, and use of technology. In addition to the cited
contributing factors, such as the cost-based reimbursement method,
lack of adequate incentive to abandon a new technology, and in-
creasing specialization in medicine, public and media demands also
significantly contribute toward feeding the "technological impera-
tive." The American public is quite sophisticated and aware of up-
to-date technologies and promising therapeutic breakthroughs,
often demanding the use of these resources for reassurance or in
support of the conventional array of physician expertise and clinical
tools. Some doctors have noted that the use of an electroencephalo-
gram is not always needed in the diagnosis of brain death but is
useful in reassuring relatives of the certainty of death.' Many pa-
tients welcome the intervention of so-called high technology and
place great value on its potential benefits, even if only for assurance
that disease is absent or has not progressed.
The media has also played a significant role in whetting the pub-
lic appetite for newer and better technologies. Both print and elec-
tronic news media have increasingly focused attention on health
care issues, responding to reports of new advances in therapies
quickly and, at times, in an almost sensationalistic manner. The
recent publicity surrounding the reports of interferon trials with
cancer patients unleashed a flood of inquiries from patients seeking
treatment. Unfortunately, as exemplified by this case, the media fo-
cused more on the potential benefits and advances than on the stark
appraisal of its risks and limitations. Dramatic stories about doc-
tors and hospitals often highlight the latest in life-saving technolo-
gies and may be quite influential in shaping public attitudes.' In the
medical literature as well, studies demonstrating the positive results
of a technology's effectiveness appear to be chosen for publication
more often than studies showing no changes or benefits-so-called
"negative" studies. Consequently, expectations and demands for
medical technology can be heightened by these influences.
In addition, cost-based reimbursement has encouraged the use
of technologies, as noted by Professor Mehlman. It also has pro-
vided no incentives to adopt simpler or cost-saving technologies.
3. See Jennett, High Technology Medicine: How Defined and How Regarded, 63
MILBANK MEMORIAL FUND Q. 141, 159 (1985).
4. See id. at 153.
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As it stands now, third-party reimbursement mechanisms provide
more generous remuneration for the use of medical and surgical
technologies than for the use of physician services, such as complet-
ing a complicated physical diagnosis, eliciting a thorough patient
history, or educating or counseling a patient. For example, an in-
ternist could triple his net income just by increasing the use of such
technologies as blood tests, electrocardiograms, and sigmoidosco-
pies, which are usually not time-intensive services.' All these atti-
tudes towards technology have contributed to the "technological
imperative."
C. The Contribution of Technologies to Rising Health Care Costs
Professor Mehlman names expensive or "big-ticket" items as at-
tracting the blame for rising costs. Indeed, the readily recognizable,
high-priced technologies have been assumed to be one of the major
culprits behind rising hospital costs. It may be useful to attempt to
describe in more detail the factors contributing to rising costs. In
turn, the definition of these factors may be helpful in choosing
which technologies may be more fruitfilly targeted for assessment
and cost-control efforts.
The Office of Technology Assessment (OTA) found that thirty
percent of the growth in costs for each Medicare enrollee was due to
both increased services as well as increases in costs for these services
above general inflation.6 The increase in services per enrollee could
be attributed to a number of factors, also alluded to by Professor
Mehlman, including the introduction of new technologies, the role
of defensive medicine in escalating the use of technologies, the
greater use of either "little-ticket" or "big-ticket" items, and the
increased use of intensive treatments for critically ill patients.7 One
recent study found that "big-ticket" imaging technologies, such as
CT scans, generally substituted for older, invasive methods, while
"little-ticket" laboratory procedures did not account for a substan-
tial portion of the increase in costs. The addition of more intensive
treatments, such as surgery for patients with heart attacks, and crit-
ical care treatment for babies with respiratory distress syndrome,
5. See Schroeder & Showstack, Financial Incentives to Perform Medical Procedures and
Laboratory Tests: Illustrative Models of Office Practice, 16 MED. CARE 289, 297 (1978).
6. See OFFICE OF TECHNOLOGY ASSESSMENT REPORT, Health Care Costs and Access
to Technology for Older Persons, in TECHNOLOGY AND AGING IN AMERICA 254 (1984).
7. See Showstack, Stone & Schroeder, The Role of Changing Clinical Practices in the
Rising Costs of Hospital Care, 313 NEw ENG. J. MED. 1201 (1985).
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were also responsible for much of the rise in costs.' It is interesting
to note that a study of the use and costs of Medicare services found
that a total of twenty-eight percent of all Medicare payments was
spent for the last year of life, almost half spent in the last sixty
days. 9
II. DEFINITION OF WASTEFUL TECHNOLOGIES AND WASTEFUL
USES OF TECHNOLOGY
The main thrust of Professor Mehlman's presentation is that the
identification and elimination of wasteful technologies, or wasteful
uses of technologies, can both help curb health care costs and en-
hance quality of care. We would definitely agree with this premise,
and we think that the analytical tools of technology assessment are
well suited for identification of waste. We would also add that tech-
nologies which are clearly recognizable as unsafe or ineffective are
more readily discarded or used sparingly by physicians. The more
recalcitrant but frequently occurring situation arises when a tech-
nology appears safe and effective, but there is insufficient knowledge
about the proportion and characteristics of the patient population
for which it can be successfully applied. Without a sufficient foun-
dation, the technology is then applied on a routine basis rather than
selectively.
This spread in the use of technologies to less effective uses has
been labeled "technology creep." 1° Some examples studied include
the routine admission chest X-ray" and the routine admission elec-
trocardiogram, 2 with results indicating a low yield in terms of new
information in the majority of hospitalized patients. Benefits from
treating mildly hypertensive patients with drugs have been shown to
be important but uncertain or infrequent, and the routine use of
such therapy would add considerably to health care costs.' 3 In
these situations, however, physicians may feel more secure and pro-
ductive by extending the use of therapies known to be effective in
8. See Id. at 1206.
9. See Lubitz & Prihoda, The Use and Costs of Medicare Services in the Last 2 Years of
Life, 5 HEALTH CARE FIN. REV., Spr. 1984, at 117, 129.
10. See Fineberg, Technology Assessment: Motivation, Capability, and Future Directions,
23 MED. CARE 663, 666 (May 1985).
11. See Hubbell, Greenfield, Tyler, Chetty & Wyle, The Impact of Routine Admission
Chest X-Ray Films on Patient Care, 312 NEW ENG. J. MED. 209 (1985).
12. See Moorman, Hlatky, Eddy, Wagner & Duke Medical House Staff, The Yield of
the Routine Admission Electrocardiogram, 103 ANNALS INTERNAL MED., Oct. 1985, at 590.




selected patients to more generalized populations, especially when
the risks appear to be absent or minimal.
Professor Mehlman describes an ineffective technology as one
that produces no discernible benefit to the patient or no positive
change in a patient's condition. In preventive medicine, of course,
it is the absence of disease or of deterioration in well-being which is
the measure of success and effectiveness. A benefit may not be "dis-
cernible" to the individual patient, yet be an important contribution
to improvement of health. One example is the polio vaccine, which
can very effectively prevent disease and disability. But in the
United States, a nonimmunized individual generally faces little risk
of exposure to the wild viral agent, and has only a very small chance
of developing the illness through immunization. Thus, healthy indi-
viduals may elect not to be immunized, since future benefits to the
individual appear uncertain, even though it is a highly effective
strategy to prevent epidemics of this paralytic disease in a suscepti-
ble society at large.
III. DEFINITION OF TECHNOLOGY ASSESSMENT
OTA's definition, which Professor Mehlman adopts, of technol-
ogy assessment as "a comprehensive form of policy research that
examines the technical, economic, and social consequences of tech-
nological applications" does not appear to fully address the breadth
of operations and objectives of technology assessment. Another
definition which was used by the National Center for Health Care
Technology (NCHCT) described technology assessment as
a form of research, analysis and evaluation that attempts to ex-
amine the various impacts of a particular technology on the indi-
vidual and society in terms of the technology's safety, efficacy,
effectiveness, and cost-effectiveness, and its social, economic, and
ethical implications, and to identify those areas requiring further
research, demonstrations and evaluations.14
Technology assessment encompasses many diverse activities
across multiple disciplines of study in a common goal: to provide
the highest quality of care possible with optimal use of available
resources. It appears that this important objective may be over-
looked in the sometimes overriding impetus for cost containment.
14. Perry, Efforts in Health Care Technology Assessment in the United States, in PRO-
CEEDINGS OF A JOINT SYMPOSIUM ON ASSESSMENT OF BIOMEDICAL TECHNOLOGY IN THE
HEALTH CARE FIELD: INTERNATIONAL PERSPECTIVES IN METHODOLOGY 100 (1981)
(published by the National Center for Health Care Technology, Public Health Service, De-
partment of Health and Human Services).
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Clearly, it will be a useful analytical method to target wasteful tech-
nologies. But in addition, technology assessment can aid in foster-
ing innovations that enhance quality of care, but that may not be
diffusing appropriately under traditional forces because of low visi-
bility or less prominent proponents. Thus, the identification of both
wasteful and useful technologies serves to promote cost-effective,
quality patient care.
A. Priority System for Technology Assessment
Professor Mehlman remarks that no widespread system to pre-
scribe priorities for assessing technologies is likely to be feasible.
However, it would seem that mutually agreed-upon criteria can be
selected. Among the criteria outlined in the article are potential
benefits, probability of risks, size of the salient patient population,
and the economic impact. Additional criteria may include a thresh-
old level of available evidence for safety and efficacy, thus eliminat-
ing from full consideration emerging technologies for which benefits
and risks are yet undetermined; presence of important ethical or
legal issues; and the likelihood that the diffusion pattern may be
distorted by economic or regulatory forces. A relative-value scale
could be devised to rank technologies into at least three categories:
low-priority, candidate, or high-priority topics.
B. Timing of Assessment Activities
In terms of the timing of technology assessment in relation to
the life cycle of technologies, Professor Mehlman points out the
merits and drawbacks of assessing emerging technologies. He notes
that although findings may prevent the entrenchment of noneffi-
cacious therapies, the risks, costs, and benefits may change rapidly
over time, outdating evaluation results quickly. Nevertheless, early
assessment may be useful to identify preliminary impressions of the
projected impact on quality of care, to note any troublesome ethical
or safety issues, and to make responsible parties aware of these
emerging technologies.
Certainly, in the clinical experimentation phase and early diffu-
sion phase, the results of technology-assessment efforts can be quite
helpful in determining appropriate practice patterns. Even when a
technology has been widely disseminated, findings of a rigorous
evaluation coupled with a broad-based effort to alert and inform
providers can promote optimal allocation of health care resources.
In addition, the need for technology assessment may vary be-
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cause of changes in the alternative choices of therapy, changes in
the techniques or applications of an existing technology, or even
changes in the character of the disease."5 For example, with the
advent of newer and more efficacious medical treatment of coronary
artery disease, the role of coronary artery bypass surgery may need
to be reexamined.
C. Costs of Technology Assessment
Professor Mehlman observes that formal technology assessment
is extremely costly, with clinical trials running into millions of dol-
lars. In some cases, the costs of assessment exceed the maximum
costs of the technology itself. It seems that technologies could be
ranked in terms of the size of the affected patient population and
overall costs, so as to eliminate these technologies from assessment
consideration. Alternatively, smaller-scale assessment procedures
could be designed.
Although it may be expensive to undertake full-scale technol-
ogy-assessment activities, it is estimated that total United States
funding for technology assessment in 1984, including industry-
sponsored clinical trials, was only $1.3 billion.16 Of this total, the
major public sector, professional, and third-party payor organiza-
tions responsible for technology assessment had an aggregate
budget of $28 million. Compared to the level of total health ex-
penditures of $424 billion in 1985,17 and an estimated $77.7 billion
for administrative costs alone,' 8 this represents a relatively small
amount. In 1985, the Institute of Medicine called for an immediate
increase of $30 million for technology-assessment activities.' 9 This
would not mean that fewer dollars would be allocated to basic re-
search. Rather, technology assessment research would complement
and augment the use of basic research findings.
IV. MAJOR ENTITIES INVOLVED IN TECHNOLOGY ASSESSMENT
Professor Mehiman describes the major parties at the forefront
of formal technology-assessment activities. Of course, as stated in
his article, the medical profession has always been involved in infor-
15. See Fineberg, supra note 10, at 669.
16. See INST. OF MED., ASSESSING MEDICAL TECHNOLOGIES (1985).
17. See Francis, US. Industrial Outlook 1986 Health and Medical Services; 3 MED.
BENEFITS-THE MEDICAL ECONOMIC DIGEST 6 (Feb. 1986).
18. See Himmelstein & Woolhandler, Cost Without Benefit: Administrative Waste in
U.S. Health Care, 314 NEw ENG. J. MED. 441, 442-43 (1986).
19. See INST. OF MED., supra note 16.
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mal technology assessments in the past and will continue to be so
involved in the future. These evaluations are based on reviews of
the literature, results of clinical trials, case reports, anecdotal expe-
rience, information gained at professional meetings, exchanges
among peers, and standards for appropriate use developed by vari-
ous specialty societies. But such evaluations, diverse in nature and
of varying scientific validity, do not always provide a coherent pic-
ture of a given technology.
Recently, the ever-expanding armamentarium of drugs, devices,
medical and surgical procedures, as well as the recognition of the
need to control costs and evaluate the broader social implications of
technology use, has led to the initiation of formal technology-assess-
ment programs. Synthesizing all the necessary data, analyses, and
viewpoints would be overwhelming for an individual physician or
policymaker. Thus, one of the functions of technology-assessment
activities should be to provide useful, objective information for
clinical and public policy decisionmaking responsibilities.
A. FDA Approval of Drugs and Medical Devices
The Food and Drug Administration (FDA) is the agency re-
sponsible for approving the safety and efficacy of new drugs and
devices. However, there are important distinctions between the ap-
proval process for drugs and for devices. All devices on the market
prior to the enactment of the Medical Device Amendments, as well
as those appearing later which were substantially equivalent to
those pre-1976 devices, were exempted from pre-market approval.
For example, the CT scanner was introduced prior to 1976 and was
automatically given marketing approval. Only Class III devices,
generally considered to be life-supporting or with potentially signifi-
cant risks for patient injury, must undergo pre-market approval.
Recently, the Medical Device Reporting Rule has been imple-
mented, and the Medicare pacemaker registry was expected to be
initiated in late 1986.
Amendments to the Food and Drug Act, enacted in 1962, re-
quire both pre-market approval and evidence of safety and effective-
ness through controlled clinical trials in the case of a new drug
application (NDA). As noted above, not all new devices require
pre-market approval. In contrast, most new drugs require an
NDA. The Orphan Drug Act provides incentives for developing
drugs for rare diseases, facilitating the use of investigational drugs
in these cases. A "me-too" drug-a new version of a drug that has
been previously marketed by another company--can be FDA-ap-
[Vol. 36:884
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proved with a shorter application and evidence of published studies
documenting safety and efficacy.'0 No such procedures exist for
medical devices.
The FDA weighs the potential benefits of a drug against its
risks, and will accept greater risks if the drug represents a signifi-
cant advance in treatment. The reporting system for drugs in post-
market surveillance was established in 1969, and consists of a data
base of adverse reactions submitted by health professionals, and also
by manufacturers who are mandated by law to report such incidents
to the FDA.
The FDA allows a physician to use an unapproved device or
product in two defined circumstances, aside from the exemptions
given for use in clinical research (called "investigational new drug
exemptions" or "INDs" and "investigational device exemptions" or
"IDEs").21 The first situation arises when a patient has not re-
sponded satisfactorily to available therapies, in which case a treat-
ment IND or IDE (or so-called compassionate IND or IDE) may
be administered. The second circumstance involves the emergency
use of an unapproved product in a life-threatening situation if other
therapies are not available. One example of an FDA determination
of an appropriate emergency use was the use of an artificial "Phoe-
nix heart" implant in Arizona in March 1985; the device had never
been approved for investigational use. 2 The Jarvik-7 heart, the
only artificial heart approved by the FDA for investigational use at
that point, was not available. It is also worthy to note parentheti-
cally that the FDA pre-market approval process may not even
strictly limit access to a device in the investigational phases. Prior
to pre-marketing approval, over forty-three Magnetic Resonance
Imaging (MRI) devices were installed.2 3
B. ProPAC's Role in Technology Assessment
We would particularly like to expand on Professor Mehlman's
discussion of the role of the Prospective Payment Assessment Com-
mission (ProPAC). He notes that ProPAC has not yet exercised its
mandate to commission technology assessments. Actually, the
20. See Pines, A Primer On New Drug Developments, in FDA CONSUMER, DHHS
(HEW) Pub. No. 81-3021 (rev. ed. July 1981).
21. See Flannery, Should it be Easier or Harder to Use Unapproved Drugs and Devices?,
16 HASTINGS CENTER REP., Feb. 1986, at 17.
22. See id. at 17-18.
23. See Steinberg, Sisk & Locke, X-Ray CT and Magnetic Resonance Imagers: Diffusion
Patterns and Policy Issues, 313 NEW ENG. J. MED. 859, 863 (1985).
1986]
CASE WESTERN RESERVE LAW REVIEW
Commission serves purely in an advisory capacity to the legislative
and executive branches of the government on the Prospective Pay-
ment System. Its two primary responsibilities are to recommend
each year appropriate update factors (the percentage change for in-
patient Medicare payments) and necessary changes in DRGs.24 Its
commitment to technology assessment was described as: limited
technology assessments and evaluation based on existing informa-
tion on safety and effectiveness and more extensive analysis of data
related to the costs and cost-effectiveness of technologies, focusing
on issues of DRG classification and payment amounts. It was not
anticipated that ProPAC would ever recommend coverage of a par-
ticular technology, but rather it would react to an announcement of
coverage, or begin an analysis if a coverage decision was
imminent.25
In addition, it appears that ProPAC's recommendations are not
always approved by the Secretary of the Department of Health and
Human Services. For example, ProPAC strongly recommended an
adjustment in 1986 for payments to hospitals serving a dispropor-
tionate share of low-income patients, but this advice was not ac-
cepted by the Secretary. ProPAC also recommended a 1.5%
increase in prospective payments for the current year, but the Secre-
tary ruled that PPS rates for inpatient hospital services be frozen for
1986.26
V. PROBLEMS IN TECHNOLOGY ASSESSMENT
A. Diagnostic Technologies
Professor Mehlman discusses the inherent problems associated
with assessing specific technologies. He notes that diagnostic tech-
nologies are difficult to assess because of both the uncertain and
often undetermined links with a therapeutic outcome and the appli-
cation of a single technology for many different purposes. This het-
erogeneity of use and results of diagnostic technologies does
account for the lack of a single value which indicates the "worth" of
24. See Prospective Payment Assessment Commission, Report and Recommendations
to the Secretary, U.S. Department of Health and Human Services, Apr. 1, 1985, 50 Fed. Reg.
24,456-24,457 (1985).
25. See The Prospective Payment Assessment Commission's Role in Technology Assess-
ment, staff paper presented at the ProPAC meeting, Washington, D.C. (July 17-18, 1985).
26. See 1986 ADJUSTMENTS TO THE MEDICARE PROSPECTIVE PAYMENT SYSTEM, RE-
PORT TO THE CONGRESS 1-3 (1985).
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many of these technologies.27 However, there are several ways to
measure the usefulness of these diagnostic methods. Each method's
efficacy can be measured in terms of detecting a specific disease or
condition by asking the question of how well it can predict the ab-
sence or presence of a disease.
Another inquiry may be its relative efficacy compared to other
available methods-how much additional information does this
method provide towards establishing the diagnosis? For example,
although CT scanning is the diagnostic method of choice for most
diseases of the central nervous system, its value in evaluating occa-
sional headaches is probably minimal when other diagnostic proce-
dures would reveal sufficient information with which to form the
diagnosis.2" Another issue concerns the value of a diagnostic test
result in influencing the decision to treat or to modify treatment.
Probably the most difficult task is to assess its value in contributing
to a patient outcome. For example, even with the benefits of earlier
and more precise diagnoses with CT scanning, patients with pancre-
atic cancer and brain tumors have not evidenced significant in-
creases in five-year survival.2 9 On the other hand, major
therapeutic breakthroughs may depend on prior evidence provided
by diagnostic studies which characterize the nature and progression
of the disease.
Another complication arises in determining the costs of the in-
troduction of new diagnostic techniques. As Professor Mehlman
describes, there is a tendency for these new technologies to "add
on" to older, more established techniques, rather than to fully sub-
stitute for older methods. In these cases, only a marginal amount of
new information is gained, which may not significantly improve the
precision of diagnosis. This tendency to employ a new technology
as an "add on" may be attributed to the providers' promotion of the
technology, efforts to refine diagnostic accuracy in comparison with
a proven method, and desires to define the anatomical regions or
disease categories for effective application. However, perhaps the
most important reason may be that the physician is more comforta-
ble with, and has more confidence in, the older technology which he
or she has used for a longer period of time.
27. See Schroeder, Medical Technology and Academic Medicine: The Doctor-Producers'
Dilemma, 56 J. MED. EDUC. 634, 637 (Aug. 1981).
28. See Diagnostic Imaging Medical Necessity Guidelines Discourage Routine Ultra-
sound, MED. DEVICE & DEVICE INSTRUMENTATION REP. I&W 1 (June 1984).
29. See Abrams, The Golden Era of Radiology: Is There Enough Gold?, 141 AM. J.
RADIOLOGY, Dec. 1983, at 1335.
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As an example of a current "add on," diffusion of MRI has
probably been slowed, at least in part, by the uncertainty over its
ability to substitute, to augment, or add on to CT scanning. Fully
thirty. to forty percent of MRI scans may substitute for the use of
CT scans in central nervous system imaging,30 but the extent of
MRI's clinical role in other cases in which both CT and MRI scans
are used is unclear. Thus, the overall costs of diagnostic imaging
for specific medical conditions may be increased in the introductory
phases of a new technology. But the cost for a single new imaging
method could actually decrease on a cost-per-case basis, as techni-
cal capabilities are improved and the service or facility operates at a
higher volume and efficiency.
Professor Mehlman also points out that initial assessments of
these technologies may be overly optimistic when actually applied
to the generalized clinical context. However, this may not always
be true. The performance and interpretive skills of physicians, as
well as the degree of technical capability of the device or equipment,
may evolve to a greater degree of sophistication and accuracy, im-
proving over the initial efficacy. In addition, advances in recent
years in the methodology used to assess diagnostic technologies take
cognizance of the issues raised when such technologies are applied
to a larger population after the initial investigative phase.
B. Medical and Surgical Procedures
Findings indicate, as Professor Mehlman points out, that medi-
cal and surgical procedures are significant components of the total
costs of patient care, which at present, are not fully addressed by
current mechanisms of technology assessment and regulation. He
notes that OTA regards this gap in assessment efforts as the "over-
riding weakness of the nation's technology assessment activities."
It was estimated that one-third of the national health care expendi-
tures in 1981, or about $90 billion, was spent for surgical care.31 In
light of the significant portion of health care costs attributed to pro-
cedures largely outside the purview of the Food and Drug Adminis-
tration and other bodies involved in assessing technologies, more
attention should be focused on designing methodologies for their
30. See PROSPECTIVE PAYMENT ASSESSMENT COMMISSION SUBCOMMITTEE ON DIAG-
NOSTIC AND THERAPEUTIC PRACTICES MEETING, PANEL PRESENTATION-PAYING FOR
COSTLY NEW TECHNOLOGIES-MAGNETIC RESONANCE IMAGING (Nov. 1985).
31. See Moore, Surgical Streams in the Flow of Health Care Financing-The Role of
Surgery in National Expenditures: What Costs Are Controllable?, 201 ANNALS SURGERY,
Feb. 1985, at 132, 134.
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evaluation. For example, Professor Mehlman describes the difficul-
ties in detecting significant changes in medical and surgical tech-
niques and the ethical problems associated with performing
controlled trials in surgical treatment. However, a few remedies
come to mind.
Although it may not be as rigorous a method as a double-blind
controlled clinical trial, a trial comparing various technologies and
techniques could be performed with common outcome measure-
ments. This would not only provide data on the safety and effec-
tiveness of each method, it would also provide information to guide
the appropriate management of particular patient subsets. For ex-
ample, a trial of antiarrhythmia treatments could compare drug
therapies, surgical techniques, closed-chest catheter techniques, and
implantable devices.
Another evaluation method involves establishing a data registry
on patient outcomes. An international registry has been established
to collect data on patients undergoing catheter ablation of the atrio-
ventricular junction: a closed-chest surgical technique to eliminate
the focus of arrhythmia origins.3 2 In addition, a number of technol-
ogies used in psychobehavioral therapy, which do not lend them-
selves easily to conventional quantitative standards and trials of
efficacy, could be subjected to assessment on the basis of outcome
measurements on a common health-sickness rating scale.3 3 In any
case, some disciplines, such as surgery and psychotherapy, have not
focused sufficient attention on the need for critical evaluation of the
techniques they employ and for developing the appropriate method-
ology to make such assessments.34
C. Methods of Assessment
The controlled clinical trial, as outlined by Professor Mehlman,
remains the best tool for determining the safety and efficacy of a
technology. He describes the ethical and cost considerations which
significantly limit the use of controlled clinical investigations.
These problems are linked to both the large patient populations
32. See Scheinman, Evans-Bell & the Executive Committee of the Percutaneous Cardiac
Mapping and Ablation Registry, Catheter Ablation of the Atrioventricular Junction: A Report
of the Percutaneous Mapping and Ablation Registry, 70 CIRCULATION, Dec. 1984, at 1024.
33. See Luborsky, Clinicians' Judgments of Mental Health: Specimen Case Descriptions
and Forms for the Health-Sickness Rating Scale, 39 BULL. MENNINGER CLINIC 448-80
(1975).
34. See Perry, The National Center for Health Care Technology: Assessment of Psycho-
therapy for Policymaking, 38 AM. PSYCHOLOGIST, Aug. 1983, at 924.
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such investigations require and study designs requiring an internal
control-withholding the technology from an appropriately
matched group. But the seriousness of these problems may depend
on the nature of the disease. For example, the evaluation of
analgesics for treatment of mild headaches, arthritis, and back pain
would not entail either large study populations or an ethical di-
lemma in withholding a new and perhaps valuable treatment.
In addition, other study designs can yield statistically valid find-
ings with fewer patients than otherwise required. Externally con-
trolled studies--clinical trials which compare subjects to historical
controls or controls in other settings-designed with explicit hy-
potheses and rationales for data interpretation and generalizability
of results can add to scientific knowledge." However, in diseases
with fluctuating natural courses (remissions and exacerbations),
matched controls are essential, as historical controls may be mis-
leading. Crossover studies-clinical trials in which responses to
two or more treatments in sequence are studied-and self-con-
trolled studies can also produce findings which may strengthen
clinical inferences.36 Even if relatively few patients are enrolled in a
study, detailed information about each individual, such as serial
measurements, may be sufficiently valid to allow for generalization
to a larger group.
Another assessment methodology is the consensus development
conference.37 Although it does not generate original data, it pro-
vides a mechanism for the synthesis and review of existing data. It
results in a summary of the state-of-the-art knowledge and serves to
identify gaps in the knowledge base, thus helping to set priorities in
research funding.38 Above all, consensus development provides a
forum where conflicting data can be scrutinized and where different
disciplines and individuals with differing perspectives can interact.
35. See Bailar, Louis, Lavori & Polansky, Statistics in Practice: Studies Without Internal
Controls, 311 NEW ENG. J. MED. 156 (1984).
36. See Louis, Lavori, Bailar & Polansky, Statistics in Practice: Crossover and Self-Con-
trolled Designs in Clinical Research, 310 NEW ENG. J. MED. 24 (1984).
37. See Perry & Kalberer, The NIH Consensus-Development Program and the Assess-
ment of Health-Care Technologies: The First Two Years, 303 NEW ENG. J. MED. 169 (1980).
38. See Perry, The Brief Life of the National Center for Health Care Technology, 307
NEW ENG. J. MED. 1095, 1097 (1982).
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VI. IMPLEMENTATION OF WASTE CONTROL
A. Role of Government and the Private Sector
in Technology Assessment
Professor Mehlman outlines the relevant advantages and disad-
vantages of a system in which the government assumes a major role
in technology assessment. One of the points made in his article is
that technology-assessment findings are similar to a public utility in
that its benefits can be applied generally; they are not restricted to
those who pay for the assessment. In light of this consideration, it
appears that a combination of public and private sources is both
desirable and essential to fund and undertake technology
assessment.
Industry is responsible for much of the technological innovation
and provides much of the impetus for the use of new technologies.
The medical profession often plants the seeds of medical innovation
and is responsible for the competent application of technologies for
promoting patient welfare. Third-party payors are responsible for
overseeing the quality and costs of care for their beneficiaries.
These entities should all be willing partners in providing assess-
ments of new and existing technologies.
B. Proposals for Roles in Evaluation and Coverage
Professor Mehlman observes that the large variety of players in
health care delivery, each with their own set of priorities for evalua-
tion of technologies, "admit to no ready solutions." However, there
have been several proposals aimed at improving medical technology
assessment in this country,3 9 and these may have stirred Congress
in late 1984 to enact legislation4° that authorized the establishment
of a council on health care technology under the aegis of the Na-
tional Academy of Sciences. As Professor Mehlman indicates, Con-
gress had previously created a federal entity with respect to
comprehensive technology assessment: the National Center for
Health Care Technology. However, under pressure from the device
39. See, eg., Bunker, Fowles & Schaffarzick, Evaluation of Medical-Technology Strate-
gies: Proposal for an Institute for Health-Care Evaluation, 306 NEW ENG. J. MED. 687
(1982); Relman, An Institute for Health-Care Evaluation, 306 NEw ENG. J. MED. 669 (1982);
Perry, Technology Assessment Proposed, 1 HEALTH AFF., Fall 1982, at 123; INST. OF MED.,
A CONSORTIUM FOR ASSESSING MEDICAL TECHNOLOGY PLANNING STUDY REPORT (Nov.
1983).
40. Health Promotion and Disease Prevention Amendments of 1984, Pub. L. No. 98-
551, 98 Stat. 2815.
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industry and the American Medical Association, the Reagan ad-
ministration acted to abolish it.
The new legislation, in effect, implements the recommendations
of a 1983 report41 by the Institute of Medicine of the Academy,
which proposed that a "consortium" be established as part of the
Institute both to serve as an information clearinghouse for medical
technology assessment and to foster communication among the
principal organizations engaged in technology assessment. The leg-
islation authorized a grant to the Institute for planning purposes on
the condition that matching funds were obtained from the private
sector. For operational purposes, funding would have to be derived
primarily from private sources with some secondary support from
the government. The establishment of such an institution should
help to address the current deficiencies in technology assessment by
facilitating exchange and coordination among the diverse groups in-
volved and by providing funds for necessary research regarding ap-
propriate use of technologies, including clinical trials (assuming
that adequate financial support is obtained).42
One suggested method of governmental involvement is to make
coverage of and reimbursement for the use of technology contingent
upon results of technology assessments. Professor Mehlman raises
an objection here, arguing that this approach may impose dispro-
portionate burdens on those who cannot afford to pay for treatment.
There appear to be a few alternatives to minimize this possibility.
During the investigational phase, device manufacturers, but not
drug manufacturers, are allowed to recover costs from users.
Although this charge may be nominal in relation to actual costs
incurred, it can indeed pose financial burdens for the institution or
for individual patients. The institutional review board should en-
sure that no candidates for clinical trials are excluded on the basis
of ability to pay. One other recourse may be to reexamine the pro-
vision for cost recovery by device manufacturers, since the new de-
vices have not yet been approved as safe and effective.
Another promising approach entails reimbursement by third-
party payors for experimental and as yet non-covered procedures
and technologies in exchange for submission of data by the provider
on the safety, effectiveness, and costs based on a mutually agreed-
41. INST. OF MED., supra note 39.




upon protocol.43 This policy would be implemented in only se-
lected clinical centers. Such an approach would expedite the acqui-
sition of information about new technologies, replacing the
unstructured and inefficient means by which such information is
currently obtained. In this manner, valuable information about a
technology could be collected and evaluated as it enters the practice
setting in order to formulate a permanent coverage decision. In ad-
dition, access to these technologies would be more equitable and
timely. Too often technology is not subjected to formal evaluation,
and data about the experience with technologies in the early stages
of clinical acceptance are lacking. Yet, they quickly are widely dis-
seminated and integrated into the practice of medicine.
C. Health Planning and Certificate-of-Need Programs
Another possible role for government is in restricting the acqui-
sition of new technology. Professor Mehlman observes that while
Certificate-of-Need Programs (CON) appear to have reduced the
number of hospital beds, they have not been effective in reducing
the acquisition of new technology. However, in the past several
years, the controls employed by CON programs have been eased or
even dropped in several states.' The current administration budget
plan for 1987 calls for an end to federal funding for health planning.
Such funding was scheduled to terminate on September 30, 1986 if
not reauthorized by Congress.45 Seven states have already repealed
CON programs. Others have deregulated certain facilities or set
threshold levels higher than those mandated by the federal rules.
And in most states, nonhospital-based outpatient facilities and phy-
sicians' offices are exempt from regulation, and thus can freely ac-
quire costly new technologies."
Objections have been raised to health planning and CON pro-
grams, probably based on a combination of impressions: 1) the pro-
grams are not effective; 2) the government is intruding and
hindering competition in the health care delivery system; and 3)
other mechanisms are available to control capital expenditures
without intrusion into allocation decisions (e.g., proposed Medicare
43. See Towery & Perry, The Scientific Basis for Coverage Decisions by Third-Party Pay-
ers, 245 J. A.M.A. 59, 61 (Jan. 1981).
44. See Perry, Rational and Irrational Diffusion of New Technologies, 1 J. HEALTH
CARE TECH., Fall 1984, at 73.
45. See Health Planning Faces New Challenges, WASH. REP. ON MED. & HEALTH-
PERSPECrIVES 3 (K. Glenn ed. Feb. 17, 1986).
46. Id.
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capital prospective payments). However, planning agencies can
also serve other functions: collecting and analyzing data, predicting
the health needs of the region, and developing plans within the com-
munities to meet those needs. In New York, local health systems
agencies target funds for primary care and maternal-child pro-
grams, and planning functions are closely linked with health policy
development functions. In New Jersey and Maryland, health plan-
ning functions are linked to the all-payor, prospective rate-setting
system.47 Thus, it appears that although planning controls have
been applied somewhat haphazardly across the nation, health plan-
ning in some areas can be used to shape and implement state health
policy in accordance with community needs, eliminating wasteful
use or duplication of technologies.
D. Regionalization
In addition to controlling the acquisition of new technologies,
health planning entities can establish medically acceptable guide-
lines for the use of expensive technologies in order to regionalize
selected technologies. In regional centers, the necessary resources,
equipment, and manpower can be marshalled in order to maintain a
high quality standard of care as well as ensure financial responsibil-
ity by operating on economies of scale. Regionalization would also
counter the inappropriate proliferation of services, with many prov-
iders competing to keep their facilities solvent.
The benefits of regionalization have been demonstrated in a
number of circumstances. For example, the regionalization of per-
inatal care has been shown to successfully decrease infant mortality
rates by eighteen percent without increasing developmental disabili-
ties.48 Studies have also shown that complication rates may be
linked to the number of procedures performed at a given center. In
the case of coronary arteriography, centers performing less than 100
procedures yearly experienced a complication rate ten times that of
centers that performed more than 400 per year.49 Thus, improved
safety and effectiveness as well as economies of scale can be
achieved through regionalization.
Some services, such as organ transplant centers, require a con-
47. Id.
48. See Regionalized Perinatal Networks Reduced Infant Mortality by 18% Without In-
creasing Disabilities, 1 TECH. REIMBURSEMENT REP.-THE BEIGE SHEET 3 (Nov. 1985).
49. See Kennedy, Kennedy, Frye, Giuliani, Pluth, Smith, Ritter & Nobregn, Use of the




siderable outlay of resources, institutional commitment, and expert
clinical management. A few states, such as Ohio and Massachu-
setts, have planned consortiums to coordinate various centers' ac-
tivities in organ procurement and patient selection. This is an
example of careful health planning efforts to conserve scarce re-
sources and to use them wisely.
VII. THE PROSPECTIVE PAYMENT SYSTEM
A. Impact on the Diffusion of Technology
The overall level of PPS and other payments to hospitals may
exert the greatest effect on technological advances and adoption.
The absence of an adequate allowance for scientific and technologi-
cal advances is likely to both restrict the diffusion of new technolo-
gies and distort patterns of access to technologies, perhaps more
than any other provision of the PPS. Historically, the average an-
nual increase between 1968 and 1980 in the intensity of services was
between four and five percent.50 Now, a hospital must fund new
acquisitions either from the "profits" left over after providing for
the care of Medicare beneficiaries or from the payments derived
from other third-party payors. Although hospitals generally re-
ported significant increases in operating profitability in 1984, it is
uncertain whether this trend can continue.5" With the probable im-
plementation of prospective rates or limitations on Medicare capital
payments in 1988, disincentives to adopt costly, new technologies
will be exacerbated.
Furthermore, since prospective rates do not currently apply to
outpatient procedures or physician fees, outpatient clinics and phy-
sicians can acquire devices and equipment and yet still collect fees
on a reasonable-cost reimbursement basis. This may lead to an in-
appropriate distribution of technology, with an increased tendency
for new technologies to be acquired by outpatient facilities. Such a
pattern may be even more costly in the aggregate and may render
new technology less accessible to patients. It is estimated that
thirty-nine percent of all MRI devices are currently situated in out-
patient settings, twice the proportion of CT scanners at a compara-
ble stage of development.5"
50. See Anderson & Steinberg, To Buy or Not to Buy: Technology Acquisition Under
Prospective Payment, 311 NEw ENG. J. MED. 182 (1984).
51. See PROSPECTIVE PAYMENT ASSESSMENT COMMISSION, Financial Consequences
for Hospitals, in MEDICARE PROSPECTIVE PAYMENT AND THE AMERICAN HEALTH CARE
SYSTEM: REPORT TO THE CONGRESS 47-50 (Feb. 1986).
52. See Steinberg, Sisk & Locke, supra note 23, at 860.
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Another issue affecting the diffusion of and access to new tech-
nologies is the timeliness of technology assessment findings.
OHTA, the federal entity responsible for providing advice to the
Health Care Financing Administration (HCFA) on Medicare cov-
erage, had a 1985 budget of only $700,000.13 In addition, FDA
approval is a necessary prerequisite for Medicare coverage. A cov-
erage decision may be announced fairly soon after approval, but it
may follow a year or more later. For example, OHTA was re-
quested in 1983 to produce an analysis of MRI devices along with a
recommendation regarding coverage. The report was not submitted
until mid-1985, and Medicare approved coverage in November of
1985-about five years after the first MRI device was installed. 4
Furthermore, the decision with respect to coverage is only the
first step under the Prospective Payment System. The two-step de-
termination establishing the payment level must then be made.
First, a new technology must be properly identified for data collec-
tion regarding costs and utilization. Until recently, no mechanism
for creating new codes existed. Second, a technology may be classi-
fied in a particular DRG or DRGs. The resulting payment determi-
nation may not reflect the true level of added resources needed for
the operating costs of the new technology. An additional problem
is that the single payment prescribed for a DRG discourages the use
of a more expensive model of a device or drug, even if it may be
more appropriate or superior. A current case in point involves the
implantation of single chamber pacemakers and dual chamber pace-
makers. Even though the dual chamber is a more expensive device
and technically more difficult to implant, both pacemaker implanta-
tions are reimbursed at the same rate.
Finally, the Prospective Payment System incorporates a long de-
lay time in price adjustment. Currently, DRG recalibration is re-
quired every four years at the very least; the 1986 rates will be based
on charge data collected in 1984; the next mandated recalibration
will not be until 1990. ProPAC has recommended to the Secretary
that recalibration occur annually, a proposal subsequently declined
by HCFA.
B. Impact on Providers
The Medicare Prospective Payment System and its incentives
encouraging providers to utilize cost-effective technologies are ex-
53. See INST. OF MED., supra note 16.
54. See Steinberg, Sisk & Locke, supra note 23, at 862.
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plicitly described by Professor Mehlman. However, since the sys-
tem still applies only to Medicare inpatient services, exclusive of
outpatient procedures and physician fees, there are implications
both for access to care and for overall expenditures, as mentioned
above. There may also be a tendency to shift any losses realized
from caring for Medicare inpatients to other third-party payors, or
to "dump" uninsured and indigent patients on other institutions if
no margin from Medicare payments exists for charity care or cross-
subsidization. This transfer of uninsured patients not only results in
a significant cost shift to public hospitals, it also creates an alarming
limitation on the access to health care for the poor." If a DRG
payment is significantly inadequate with respect to the true costs of
the necessary resource use, an unfair burden is placed on some insti-
tutions, which can limit access to care to Medicare inpatients.
PPS rates are based on historical charge and cost data, which
tend to reflect the traditional cross-subsidization of expensive proce-
dures with less expensive services within hospital billing patterns. 6
Thus, more complicated technologies tend to be underpriced in
DRG rates, and hospitals may benefit by deleting these services and
transferring certain patients elsewhere, even if the technology is cost
effective in the long run.
Professor Mehlman states that the variation in Medicare reim-
bursement policy at the contractor level may provide advantages,
such as accommodating new technologies in a more flexible man-
ner. It is true that intermediaries may exercise their discretion prior
to a national coverage decision. However, this may also have sev-
eral drawbacks. For instance, the technology may not be safe or
effective or truly beneficial, findings which may have been revealed
by a formal assessment provided to HCFA by the Public Health
Service (PHS). It also creates inequities in access to care for Medi-
care beneficiaries across the nation. In addition, data accrual on the
application of new technologies on a nonsystematic basis is gener-
ally minimal, as would be expected if coverage were inconsistently
applied. It would appear that HCFA has potential access to enor-
mous amounts of data, but its data collection system is deficient. In
any case, the lack of uniformity in coverage creates uncertainty on
the part of providers, manufacturers, and patients. It appears to be
in the best interests of patients and providers to promulgate clear,
55. See Schiff, Ansell, Schlesser, Indris, Morrison & Whitman, Transfer to a Public Hos-
pital: A Prospective Study of 467 Patients, 314 NEw ENG. J. MED. 552, 556 (1986).
56. See Steinberg, Sisk & Locke, supra note 23, at 862.
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enforceable rules for Medicare coverage, as Professor Mehlman
suggests.
C. Impact on Manufacturers
Professor Mehlman outlines the various forces which may im-
pact on the behavior of manufacturers and others who develop new
technologies. Although it is a complicated process, which in some
degree is insensitive to market forces, there is evidence that manu-
facturers are increasingly emphasizing the relative efficacy and cost-
effectiveness of technologies. This trend has been more prominent
in the marketing approaches for existing devices, since the research
and development (R&D) of these devices began several years before
the incentives created by the PPS emerged. One medical device
manufacturer has established screening mechanisms to evaluate
R&D efforts with respect to short-term cost effectiveness, and has
attempted to develop short-term cost-effective devices specifically to
be used in particular DRG categories.57 As another example, a
drug manufacturer has advertised that the use of a new antibiotic
will not be charged to the provider if the patient's hospital stay ex-
ceeds the average length-of-stay for the DRG payment level.
In a marked change, the Health Industry Manufacturers Associ-
ation (HIMA) was focusing on technology assessment as one of its
priority areas in 1986, exploring "relative efficacy" criteria and re-
search programs to collect health outcome information, such as sur-
vival rates and impact on quality of care.58 This responsiveness to
cost-constraint pressures on the part of industry, coupled with other
public and private initiatives, may constructively address the prob-
lem of wasteful technologies.
Research and development of technologies may also be nega-
tively affected, potentially altering the rate of innovation. Compa-
nies may decide not to pursue costly technological advances because
of the uncertainty of demand and reimbursement. This will be ben-
eficial if it results in the production of fewer marginal or inefficient
technologies, but it may be harmful if advances in the quality of
care are stifled. Greater standardization in product mix is likely,
and financially limited small companies may be forced out of the
57. See Bessey, Don't Let Cost Containment Stifle Technological Innovation, presented at
the 1985 Harold and Jane Hirsch Symposium at George Washington University.
58. See Use of "Relative Efficacy" Criteria Is Part of HIMA Study on Technology Assess-




market due to competitive pressures and uncertainties of
reimbursement.
D. Conflict of Interest Embodied in Current
Cost-Containment Initiatives
In his article, Professor Mehlman comments on the shortcom-
ings of the current combination of prospective payment and cover-
age determination for implementing controls on wasteful
technology. He very aptly describes the system as creating distinct
incentives for cost-reducing technologies, which are not necessarily
disincentives for wasteful technologies. This bias not only creates a
conflict of interest between the provider or investor physician and
patient, but also between the primary care provider and institu-
tional administrator. The physician's primary responsibility is to
act in the best interests of his or her own patients. The hospital
administrator's duty is owed to all the patients receiving care at the
hospital, as well as to the financial viability of the institution. In
addition, the physician who is an investor in a facility in which he
or she is employed or to which he or she can refer patients is in a
serious conflict-of-interest situation.
The growth of competition under the PPS can create pressures
to lower per-unit costs of technologies, but can also induce provid-
ers to unbundle expensive services, generate new services or repeat
procedures unnecessarily, and increase the volume of services for
which payment is received. In addition, in view of the growing
trend and size of corporation-owned hospitals and for-profit institu-
tions, the physician "employee" may begin to lose some of his or
her traditional autonomy and influence in placing the patient's in-
terests foremost.
E. Quality of Care Concerns
Professor Mehlman states that Medicare's PPS has not been in
effect long enough to permit evaluation of its impact on quality of
care, including the development, acquisition and use of technolo-
gies. While it is true that data does not presently exist directly link-
ing reductions in the quality of care to the PPS forces, the studies
thus far have not generally focused on the entire episode of care,
including post-hospitalization treatment. Outcome may not be ade-
quately determined until a period of time after the inpatient stay has
elapsed.
Peer Review Organizations (PROs) have generally focused on
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review of admissions, procedures, outliers, and readmissions. 9 The
scope of PRO review of quality of care has been restricted to inpa-
tient services, exclusive of outpatient care, home care, and nursing
home care. The General Accounting Office Report for the Senate
Committee on Aging noted that the number of home health agen-
cies increased and were dealing with more complicated case loads
after the implementation of PPS.60 In addition, surveys of the
membership of both the American Medical Association and the
American Society of Internal Medicine revealed that a majority of
physicians perceived a deterioration in quality of care or pressures
to discharge patients prematurely.61
Another explanation for the evident lack of complaints about
the quality of care is that beneficiaries have perceived that Medicare
limits the number of days of care per hospitalization. They have
also been unaware of their rights to recourse or appeal if they felt
that they had been or were about to be discharged prematurely.
Although PPS was implemented in late 1983 and early 1984,
HCFA did not have any general information for distribution to ben-
eficiaries until spring of 1985. Only recently has a mechanism been
established to routinely distribute fact sheets to beneficiaries at the
time of admission aimed at informing them about their rights to
appeal a hospital's denial of additional inpatient services before
discharge.
The new scope of PRO oversight proposed by HCFA in Novem-
ber, 1985, includes generic quality screens to determine adequacy of
discharge planning, stability at discharge, and morbidity and mor-
tality rates during hospitalization. The proposal also provides for
assistance in improving information dissemination to beneficiaries
regarding PPS and their rights in the appeals process. However, no
funds are presently provided for review of services outside the hos-
pital setting.62
F. Future Implications
Although it is generally accepted that PPS will have to be modi-
59. See DRGs and Quality of Care, WASH. REP. ON MED. & HEALTH-PERSPECTIVES
3 (S. Williams ed. Nov. 25, 1985).
60. General Accounting Office Letter Report to the Senate Special Committee on Ag-
ing-"Information Requirements for Evaluating the Impact of Medicare's Prospective Pay-
ment System on Post-Hospital Care" (GAO/PEMD-85-8).
61. See DRGs and Quality of Care, supra note 59, at 3.
62. See ProPAC's Report to Congress, WASH. REP. ON MED. & HEALTH-PERSPEC-
TIVES 306 (K. Glenn ed. Mar. 10, 1986).
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fled and the concept probably extended, certain implications of the
effects of PPS seem apparent at this time. While hospitals generally
profited under Medicare's PPS in 1984, it is predicted that, in the
transition to national rates, some large rural hospitals and hospitals
located in the East and West-North-Central regions will suffer sig-
nificant losses. It is not clear that differences in payment distribu-
tions to hospitals reflect differentials in operating efficiency.63
Proposed regulations issued by HCFA specify that reasonable, na-
tional ceiling rates may be prescribed for payments for new expen-
sive technology or new efficiencies in the use of existing
technology.' 4 This would signify a departure from the general pol-
icy of basing payments on historical charge data. Factors that
might be considered in establishing payment limits could include
the price markup in comparison with similar services, a cost-effec-
tive utilization rate, and the costs of providing the service. This
proposed limit for new technologies could significantly affect diffu-
sion patterns.
For example, ProPAC recently voted to recommend an add-on
payment of $124 for hospitals that possess MRIs and are receiving
capital payments, and an add-on payment of $282 for hospitals con-
tracting with another hospital for MRI services.65 This payment
level is based not only on cost and charge data obtained from hospi-
tal experience, but also on a desired level of medium to high effi-
ciency of operation. A 1985 analysis of MRI units in the United
States indicated that at the present volume of operation, the break-
even economic point would be $1084 per scan; at a high volume of
operation, the break-even point would be $635 per scan.66 If the
payment level is set significantly below costs, access to these services
by Medicare patients could be limited. Such payment levels could
even encourage duplication and unnecessary use in order to achieve
a high volume of services. Proposed MRI payments would be paid
from the general allowance for scientific and technological ad-
vances, thus reducing the available funds for other new technologies
or for hospitals not utilizing MRI scans.
63. Id.
64. See New Expensive Technology is Among Cases Where HCFA May Set National
Medicare Charge Limits, 2 TECH. REIMBURSEMENT REP.- THE BEIGE SHEET 3 (Feb.
1986).
65. See Prospective Payment Assessment Commission, Report and Recommendations
to the Secretary, U.S. Department of Health and Human Services 53-54 (Apr. 1, 1986).
66. See Evens, Jost & Evens, Economic and Utilization Analysis of Magnetic Resonance
Imaging Units in the United States in 1985, 145 AM. J. RADIOLOGY, Aug. 1985, at 393.
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VIII. LEGAL PRESSURES AS INCENTIVES TO PROVIDE
COSTLY TECHNOLOGIES
Professor Mehlman describes the legal pressure which is encour-
aging providers to furnish non-wasteful but cost-increasing technol-
ogy, namely the fear of malpractice suits. He also observes that,
historically, malpractice law favors the patient perspective over the
interests of the providers and payors. Although these legal stan-
dards have provided a strong impetus for providers to utilize costly
technologies in patient care, they have also led to wasteful use of
technologies in order to ensure a defensible stance against any mal-
practice claim. The Arierican Medical Association estimates that
$15 billion a year is spent on defensive medicine. A 1983 survey of
physicians noted that 40.8% of respondents prescribed additional
diagnostic tests, and 34.6% prescribed additional treatment proce-
dures in response to pressures of possible litigation.67
Another interesting point raised by Professor Mehlman is the
possibility that the medical profession may adopt the attitude that a
cost-increasing technology can no longer be justified, although it
may enhance quality. Would this be sustained in a court of law as
an accepted standard of care? It appears unlikely as long as physi-
cians continue to serve the patient's best interests, and society val-
ues the patient higher than payor and provider interests. For
instance, it is doubtful that Americans would accept the rationing
process inherent in the National Health Service (NHS) in Great
Britain. Because of economic constraints, physicians in the NHS
must allocate scarce resources among patients and among various
technologies." Confronted with these decisions, it appears that the
physician has, in some cases, incorporated economic restrictions
into the medical standards of care.6 9 An elderly patient with kidney
failure may not be told of the possibilities of treatment with dialysis,
and a patient with chest pain may not qualify for the relatively re-
strictive criteria for coronary artery bypass surgery. It is of interest
to note, however, that questions have been recently raised in this
circumstance concerning the patient's right to treatment, the doc-
tor's duty to his or her patient, and the possibility that the doctors
could be committing a crime by knowingly withholding beneficial
67. See Zuckerman, Medical Malpractice: Claims, Legal Costs, and the Practice of De-
fensive Medicine, 3 HEALTH AFF., Fall 1984, at 128, 131.
68. See Schwartz & Aaron, Rationing Hospital Care: Lessons from Britain, 310 NEw
ENG. J. MED. 52 (1984).




Medical rationing through the use of socioeconomic criteria
would be anathema in the United States. It would generally be re-
garded as unacceptable for maintaining either the public confidence
in medical care or the equal opportunities implicit in the promises
of accessible health services. However, in some sense, the cost-con-
trol measures in place with prospective rates, capitated systems, and
regulation over coverage and acquisition of technologies act as ra-
tioning devices, and such devices are being implemented when re-
sources are constrained. For example, bed availability affects the
admission and discharge decisions of physicians working in inten-
sive care units (ICU). The most important concern is that when
beds are scarce, the physician may have to rely on schemes for risk
stratification of patients according to reasonable expectations of and
sound information about the safety, effectiveness, and appropriate
use of the technologies employed.
Although most people have access to a reasonably high standard
of care, there are many who, due to geographical, cultural, and eco-
nomic barriers, do not have access to some of the more sophisti-
cated services and technologies. A source of increasing concern is
the access to care for the poor, disabled, and elderly.71 The new
initiatives in cost containment in the publicly funded programs for
Medicare and Medicaid may exacerbate the differentials in access to
care for these groups. Under the PPS, a larger proportion of health
care costs have been passed on to the beneficiary in the form of
higher premiums, higher deductibles, and greater use of outpatient
services, including nursing home care (which is not usually reim-
bursed under Medicare).72
IX. CONCLUSIONS
The impetus for cost containment has led to increased interest
and efforts in technology assessment in order to define appropriate
and inappropriate uses of technology. It is clear that many new
technologies enter the practice arena, some of which involve costs
beyond reasonably anticipated benefits, some of which may be ap-
plied on a wasteful basis, and some of which have great promise to
improve quality of care. It is also clear that current competitive
70. See Brahams, End-Stage Renal Failure: The Doctor's Duty and the Patient's Right, 1
LANC ET 386 (1984).
71. See Mechanic, Cost Containment and the Quality of Medical Care: Rationing Strate-
gies in an Era of Constrained Resources, 63 MILBANK MEMORIAL FUND Q. 453 (1985).
72. See ProPac's Report to Congress, supra note 62.
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incentives, regulatory controls, and the Prospective Payment Sys-
tem cannot be relied upon alone to foster the appropriate decision-
making regarding new and existing uses of technologies. Professor
Mehlman concludes that although there exist technical and concep-
tual difficulties, technology assessment is inevitable and, we would
add, desirable to assess the most crucial step in health care delivery:
determining how a technology can be best used in patient care.
While there are many uncertainties facing the future of our health
care system, including questions of how much health care we can
afford, there are also new opportunities to influence the delivery of
health care with careful planning and evaluation.
Of note is the intensified interest in technology assessment in the
private sector, composed of professional organizations, industry,
third-party payors, universities, and provider organizations. The
establishment of the Council on Health Care Technology at the In-
stitute of Medicine (IOM), a public-private entity charged with as-
sessing health care technologies and with coordinating information
exchange and evaluation efforts, could help to fill a much-needed
role to form a coherent, formal mechanism for technology assess-
ment.73 In addition, a system is needed to set assessment priorities
among technologies and to fund research projects, including clinical
trials to determine safety, effectiveness, and the relative efficacy of
technologies. Whether the IOM Council will acquire the requisite
resources remains to be seen.
Another step in the systematic assessment of new technologies
should be to establish programs for the interim coverage and reim-
bursement of new technologies as they enter the practice setting.
Such a program would fill an important gap in knowledge about
medical technologies-the experience in the real world of the prac-
tice of medicine. Such programs could target selected study sites
and protocols. In exchange for payment, providers would supply
data on safety, effectiveness, costs, and cost-effectiveness of a given
technology based on a predetermined protocol. This program
would augment the process of decisionmaking for third-party reim-
bursement, as well as provide more equitable access to new
technologies.
The results of technology assessment can be used in making ap-
propriate allocation decisions, providing an objective evaluation
prior to the routine use of technologies in clinical practice. For ex-
ample, expensive, new technologies, such as organ transplants,
73. See Perry, supra note 42, at 242.
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MRI, or cardiac catheterization procedures, can be regionalized.
This would prevent wasteful duplication of services and promote a
level of use commensurate with economic feasibility and staff
proficiency.
Another result of technology-assessment efforts lies in providing
guidance and information to engender more cost-effective and ap-
propriate clinical practice patterns. Wennberg's studies have
demonstrated the highly discretionary character of medical care de-
cisions, which correlate with differences among physicians and their
practice styles.7 4 A broader consensus on the appropriate use of
medical technologies can help to determine which practice patterns
can be most beneficial for patients. In addition, appreciation of the
factors contributing to the process of clinical decisionmaking would
appear to reflect a more refined strategy to control per-capita costs
when compared to prescribing a price for a hospitalization or for a
technology.
Professor Mehlman appropriately views with misgivings the im-
plementation of a Medicare reimbursement system that creates a
conflict of interest between patients and providers, thereby encour-
aging providers to withhold technologies that might be in the pa-
tient's interests but that increase provider costs. Indeed, greater
vigilance needs to be focused upon the potential inequities of the
PPS: the ripple effects felt in the other sectors of the health care
system; the unequal burdens it may place on different patient
groups or providers; and, in the long run, consequences for the
quality of care. A set of new technologies could be studied as case
examples of technology diffusion under PPS, and aspects of the sys-
tem which cause distortions in patterns of diffusion could be identi-
fied and reevaluated. In these examples, effects of reimbursement
decisions, risks of over or under diffusion, the relationship of
demonstrated evidence of safety and effectiveness to clinical accept-
ance and dissemination patterns could be studied. The scope of
quality review by PROs should encompass the entire episode of pa-
tient management: diagnosis, treatment, as well as post-hospitaliza-
tion care.
In summary, there is a recognized need for a rational, coherent
system to identify and assess health care technologies, to reduce the
use of less efficacious services, and to accommodate the use of
proven, effective technologies. Medicine has been a discipline char-
74. Wennberg, Dealing with Medical Practice Variations: A Proposal for Action, 3
HEALTH AFF., Summer 1984, at 6.
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acterized by dynamic scientific development, and the future
promises to bring an ever-increasing number of technological ad-
vances. Challenges to manage the increased demand in an equitable
fashion will have to be met. Technology assessment can be the ana-
lytic tool for use by the diverse parties involved in promoting the
appropriate and discriminate use of resources in order to enhance
both the quality and cost effectiveness of care.
